STING agonist-3 is primarily utilized in the field of immunotherapy, particularly for its role in activating the STING (Stimulator of Interferon Genes) pathway. This activation leads to the production of type I interferons and other pro-inflammatory cytokines, which are crucial for enhancing the immune system's response against cancer cells. It is being explored as a potential therapeutic agent in cancer treatment, especially for tumors that are resistant to conventional therapies. Additionally, it is being studied for its potential use in vaccines to boost immune responses against infectious diseases. Its ability to modulate the immune system makes it a promising candidate for various immunotherapeutic applications.